Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122011 | 0.89 | DGAT1 (0.33) | ADORA2B | |
| SCHEMBL21153189 | 0.86 | ADORA2B (0.31) | ADORA2B | |
| SCHEMBL21121991 | 0.84 | SYK (0.34) | ADORA2B | |
| SCHEMBL15998450 | 0.81 | ADORA2B (0.44) | ADORA2B | |
| SCHEMBL21121438 | 0.80 | ADORA2B (0.39) | ADORA2B | |
| SCHEMBL23067580 | 0.79 | ADORA2B (0.49) | ADORA2B | |
| SCHEMBL23067600 | 0.78 | ADORA2B (0.38) | ADORA2BTLR7 | |
| SCHEMBL23067606 | 0.76 | ADORA2B (0.44) | ADORA2B | |
| SCHEMBL23067602 | 0.76 | ADORA2B (0.47) | ADORA2B | |
| SCHEMBL23067590 | 0.75 | ADORA2B (0.60) | ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| CN-111770926-B | Tricyclic compounds, compositions and pharmaceutical uses thereof | 因佩蒂斯生物科学有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-11407758-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2022-08-09 | — | — | US | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | ADRA1A 14/4885KCNH2 2866/4885HRH3 2222/4885 |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ADRA1A 25/4885KCNH2 3415/4885HRH3 1490/4885 |
| US-11407758-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA3, ADORA1 | ADRA1A 25/4885KCNH2 3415/4885HRH3 1490/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | ADRA1A 14/4885KCNH2 2866/4885HRH3 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.